Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,083 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: polysaccharide Clear all
Completed Phase 2Phase 3 Interventional Results available

A Trial to Improve Quality of Life in People With Cirrhosis

NCT05061992
View directory record Official record
Conditions
Cirrhosis
Interventions
Lactulose
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma

NCT00037011
View directory record Official record
Conditions
Neuroblastoma
Interventions
beta-glucan, monoclonal antibody 3F8
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 49 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Results available

Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery

NCT03112993
View directory record Official record
Conditions
Spine Surgery
Interventions
sugammadex, Neostigmine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

NCT02798471
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
Interventions
Edoxaban, Standard of Care
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Day to 17 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients

NCT01585350
View directory record Official record
Conditions
Melanoma
Interventions
MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS), MELITAC 12.1 + Montanide ISA-51 + polyICLC
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 19, 2026, 8:29 AM EDT
Suspended Phase 1Phase 2 Interventional

Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

NCT01562626
View directory record Official record
Conditions
Tumors, Neoplasms, Cancer
Interventions
APS001F, Flucytosine (5-FC), 10% maltose
Drug
Lead sponsor
Anaeropharma Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
2
States / cities
Minneapolis, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Results available

To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection

NCT01895959
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Euflexxa, Magnetic Resonance Imaging (MRI)
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

NCT04401176
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Heparin & Alkalinized Lidocaine Bladder Instillation, Onabotulinum Toxin A
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 19, 2026, 8:29 AM EDT
Not yet recruiting Not applicable Interventional

Comparing Prebiotic Fiber Supplements for Gut Health and Digestive Comfort

NCT07525180
View directory record Official record
Conditions
Healthy Participants
Interventions
LOAM, Inulin, Cellulose Placebo
Dietary Supplement
Lead sponsor
Ventoscity LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes

NCT03655535
View directory record Official record
Conditions
Type2 Diabetes Mellitus
Interventions
BTI320, Placebo
Drug · Other
Lead sponsor
Boston Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Ventura, California • Albuquerque, New Mexico • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

NCT03480802
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Orlando, Florida • West Palm Beach, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 19, 2026, 8:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

NCT06866262
View directory record Official record
Conditions
Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Inulin, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration
Procedure · Dietary Supplement · Biological + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 19, 2026, 8:29 AM EDT
Terminated Not applicable Interventional Results available

Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer

NCT04779489
View directory record Official record
Conditions
Bladder Cancer
Interventions
personalized ultrafractionated stereotactic ablative radiotherapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 19, 2026, 8:29 AM EDT
Recruiting Phase 2 Interventional

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

NCT06004674
View directory record Official record
Conditions
Adverse Pregnancy Outcome
Interventions
Lovenox 40mg
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

NCT05464420
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
V116, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
2,162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
30
States / cities
Mesa, Arizona • Tempe, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

NCT03691610
View directory record Official record
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine, Haemophilus b Conjugate Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 19 Months
Enrollment
950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 3 Interventional

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

NCT00345618
View directory record Official record
Conditions
Embolism, Thrombosis
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of D-allulose in Addition to Oral Sucrose Load

NCT02714413
View directory record Official record
Conditions
Blood Glucose
Interventions
D-allulose, sucrose, Placebo
Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Characterize the Effect of Heparin on Palifermin Activity

NCT01163097
View directory record Official record
Conditions
Oral Mucositis
Interventions
Palifermin, Heparin
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 19, 2026, 8:29 AM EDT
Withdrawn Phase 4 Interventional

Rifaximin Versus Lactulose in Renal Failure

NCT00748904
View directory record Official record
Conditions
Liver Cirrhosis, Renal Failure
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rescuing the Microbiome Effectively With Different Doses of B. Infantis in Infants

NCT03476447
View directory record Official record
Conditions
Gut Microbiome
Interventions
B. infantis EVC001, Lactose
Other
Lead sponsor
Evolve BioSystems, Inc.
Industry
Eligibility
2 Months to 4 Months
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 19, 2026, 8:29 AM EDT
Withdrawn Phase 2 Interventional

Safety of Heparin in Patients With Septic Shock

NCT01234285
View directory record Official record
Conditions
Sepsis
Interventions
heparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 19, 2026, 8:29 AM EDT
Terminated Phase 4 Interventional Results available

Aspirin and Enoxaparin for VTE in Trauma

NCT02396732
View directory record Official record
Conditions
Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions
Aspirin, Enoxaparin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263
View directory record Official record
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 19, 2026, 8:29 AM EDT